Cargando…

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia

Hemophilia A and B are bleeding disorders caused by a deficiency of clotting factor VIII and IX, respectively. Patients with severe hemophilia (< 0.01 IU mL(−1)) and some patients with moderate hemophilia (0.01–0.05 IU mL(−1)) administer clotting factor concentrates prophylactically. Desmopressin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Preijers, Tim, Schütte, Lisette M., Kruip, Marieke J. H. A., Cnossen, Marjon H., Leebeek, Frank W. G., van Hest, Reinier M., Mathôt, Ron A. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808974/ https://www.ncbi.nlm.nih.gov/pubmed/32936401 http://dx.doi.org/10.1007/s40262-020-00936-5

Ejemplares similares

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
por: Schütte, Lisette M, et al.
Publicado: (2019)

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
por: Preijers, Tim, et al.
Publicado: (2021)

Desmopressin testing in von Willebrand disease: Lowering the burden
por: Heijdra, Jessica M., et al.
Publicado: (2022)

Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice
por: Goedhart, Tine M. H. J., et al.
Publicado: (2021)

The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority?
por: Schütte, Lisette M., et al.
Publicado: (2020)

Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study
por: Heijdra, Jessica M, et al.
Publicado: (2022)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
por: Goedhart, Tine M.H.J., et al.
Publicado: (2022)

Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients
por: Preijers, Tim, et al.
Publicado: (2021)

In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
por: Preijers, T., et al.
Publicado: (2021)

Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Desmopressin in moderate hemophilia A patients: a treatment worth considering
por: Loomans, Janneke I., et al.
Publicado: (2018)

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy
por: Romano, Lorenzo G.R., et al.
Publicado: (2023)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation
por: Bukkems, Laura H., et al.
Publicado: (2023)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
por: Bukkems, Laura H., et al.
Publicado: (2023)

Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients
por: van Moort, Iris, et al.
Publicado: (2020)

Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding
por: Atiq, Ferdows, et al.
Publicado: (2021)

Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients
por: Romano, Lorenzo G. R., et al.
Publicado: (2022)

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
por: Iorio, Alfonso, et al.
Publicado: (2018)

Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?
por: Goedhart, Tine M.H.J., et al.
Publicado: (2022)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

The History of Clotting Factor Concentrates Pharmacokinetics
por: Morfini, Massimo
Publicado: (2017)

Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2021)

Hemophilia B in a female with intellectual disability caused by a deletion of Xq26.3q28 encompassing the F9
por: Stoof, Sara C. M., et al.
Publicado: (2018)

Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients
por: de Winter, Brenda C. M., et al.
Publicado: (2009)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Current and Emerging Options for the Management of Inherited von Willebrand Disease
por: Heijdra, Jessica M., et al.
Publicado: (2017)

Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2022)

Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review
por: Hodiamont, Caspar J., et al.
Publicado: (2022)

Paracetamol clinical dosing routine leads to paracetamol underexposure in an adult severely ill sub-Saharan African hospital population: a drug concentration measurement study
por: Bos, Jeannet C., et al.
Publicado: (2017)

Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling
por: Janssen, Alexander, et al.
Publicado: (2022)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
por: Yu, Jacky K., et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Target Attainment of Ceftazidime in Adult Patients on General Wards with Different Degrees of Renal Function: A Prospective Observational Bicenter Cohort Study
por: Zieck, Saskia E., et al.
Publicado: (2023)

CANINE HEMOPHILIA : OBSERVATIONS ON THE COURSE, THE CLOTTING ANOMALY, AND THE EFFECT OF BLOOD TRANSFUSIONS
por: Graham, John B., et al.
Publicado: (1949)

Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic‐pharmacodynamic model for patients with haemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

STUDIES ON BLOOD COAGULATION : IV. THE NATURE OF THE CLOTTING DEFICIENCY IN HEMOPHILIA
por: Eagle, Harry
Publicado: (1935)

DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A
por: Donners, Anouk, et al.
Publicado: (2023)

Deep compartment models: A deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling
por: Janssen, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nvf88dmpntajtlkq7f4ikn6l5u